Finance

First quarter 2002 performance: net loss of $0.29 per share

Published in Vaccine Weekly, June 12th, 2002

GenVec, Inc., (GNVC), a biopharmaceutical company developing gene-based medicines, announced financial results for the first quarter ended March 31, 2002. GenVec reported a net loss of $6.4 million or ($0.29) per share compared with a net loss of $3.3 million or ($0.18) per share in the comparable quarter of 2001. GenVec ended the first quarter of 2002 with $34.4 million in cash and investments.

Revenues for the quarter ended March 31, 2002 were $628,000 compared with $2.0 million for the same period last year. Revenue for the current quarter was primarily attributable to the commencement of activities under the company's new $10.2 million collaboration with the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-06-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry